SNDX
Income statement / Annual
Last year (2025), Syndax Pharmaceuticals Inc's total revenue was $172.35 M,
an increase of 627.84% from the previous year.
In 2025, Syndax Pharmaceuticals Inc's net income was -$285.42 M.
See Syndax Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$172.35 M |
$23.68 M |
$0.00 |
$0.00 |
$139.71 M |
$1.52 M |
$1.52 M |
$1.52 M |
$2.11 M |
$1.22 M |
| Cost of Revenue |
$6.97 M
|
$826.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$165.38 M
|
$22.85 M
|
$0.00
|
$0.00
|
$139.71 M
|
$1.52 M
|
$1.52 M
|
$1.52 M
|
$2.11 M
|
$1.22 M
|
| Gross Profit Ratio |
0.96
|
0.97
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$258.78 M
|
$241.65 M
|
$163.03 M
|
$118.50 M
|
$88.25 M
|
$50.44 M
|
$42.99 M
|
$60.11 M
|
$48.20 M
|
$31.67 M
|
| General & Administrative Expenses |
$179.68 M
|
$120.88 M
|
$66.92 M
|
$33.26 M
|
$25.24 M
|
$22.51 M
|
$16.06 M
|
$17.29 M
|
$15.86 M
|
$13.32 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$179.68 M
|
$120.88 M
|
$66.92 M
|
$33.26 M
|
$25.24 M
|
$22.51 M
|
$16.06 M
|
$17.29 M
|
$15.86 M
|
$13.32 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$438.47 M
|
$362.53 M
|
$229.95 M
|
$151.76 M
|
$113.49 M
|
$72.94 M
|
$59.06 M
|
$77.39 M
|
$64.06 M
|
$44.99 M
|
| Cost And Expenses |
$445.44 M
|
$363.35 M
|
$229.95 M
|
$151.76 M
|
$113.49 M
|
$72.94 M
|
$59.06 M
|
$77.39 M
|
$64.06 M
|
$44.99 M
|
| Interest Income |
$22.73 M
|
$26.09 M
|
$21.16 M
|
$5.87 M
|
$403.00 K
|
$841.00 K
|
$1.57 M
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$33.79 M
|
$4.93 M
|
$208.00 K
|
$3.14 M
|
$1.90 M
|
$2.36 M
|
$0.00
|
$1.94 M
|
$1.42 M
|
$956.00 K
|
| Depreciation & Amortization |
$6.00 K
|
$8.00 K
|
$12.00 K
|
$33.00 K
|
$43.00 K
|
$515.00 K
|
$451.00 K
|
$78.00 K
|
$76.00 K
|
$89.00 K
|
| EBITDA |
-$251.63 M |
-$313.82 M |
-$209.14 M |
-$146.17 M |
$26.87 M |
-$70.29 M |
-$55.60 M |
-$73.88 M |
-$61.88 M |
-$43.68 M |
| EBITDA Ratio |
-1.46
|
-13.25
|
0
|
0
|
0.19
|
-46.33
|
-36.65
|
-48.7
|
-29.35
|
-35.8
|
| Operating Income Ratio |
-1.58
|
-14.34
|
0
|
0
|
0.19
|
-47.08
|
-37.93
|
-50.02
|
-29.39
|
-35.87
|
| Total Other Income/Expenses Net |
-$12.34 M
|
$20.91 M
|
$20.59 M
|
$2.42 M
|
-$1.29 M
|
-$1.74 M
|
$1.49 M
|
$1.92 M
|
$1.15 M
|
-$706.00 K
|
| Income Before Tax |
-$285.42 M
|
-$318.76 M
|
-$209.36 M
|
-$149.34 M
|
$24.93 M
|
-$73.16 M
|
-$56.05 M
|
-$73.96 M
|
-$60.80 M
|
-$44.47 M
|
| Income Before Tax Ratio |
-1.66
|
-13.46
|
0
|
0
|
0.18
|
-48.23
|
-36.95
|
-48.75
|
-28.84
|
-36.45
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$76.00 K
|
-$89.00 K
|
| Net Income |
-$285.42 M
|
-$318.76 M
|
-$209.36 M
|
-$149.34 M
|
$24.93 M
|
-$73.07 M
|
-$55.96 M
|
-$73.96 M
|
-$60.80 M
|
-$44.47 M
|
| Net Income Ratio |
-1.66
|
-13.46
|
0
|
0
|
0.18
|
-48.17
|
-36.89
|
-48.75
|
-28.84
|
-36.45
|
| EPS |
-3.29 |
-3.73 |
-2.98 |
-2.46 |
0.48 |
-1.77 |
-1.84 |
-2.92 |
-2.9 |
-3.04 |
| EPS Diluted |
-3.29 |
-3.73 |
-2.98 |
-2.46 |
0.48 |
-1.77 |
-1.84 |
-2.92 |
-2.9 |
-3.04 |
| Weighted Average Shares Out |
$86.63 M
|
$85.62 M
|
$70.37 M
|
$60.76 M
|
$52.06 M
|
$41.31 M
|
$30.49 M
|
$25.37 M
|
$21.00 M
|
$14.62 M
|
| Weighted Average Shares Out Diluted |
$86.63 M
|
$85.62 M
|
$70.37 M
|
$60.76 M
|
$52.06 M
|
$41.31 M
|
$30.49 M
|
$25.37 M
|
$21.00 M
|
$14.62 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
